Clinical Trial Update: EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction) [Phase 3]

View source ↗

Summary

Phase 3 EMPACT-MI trial evaluating whether empagliflozin reduces the risk of heart failure and death in people who had a myocardial infarction; results have bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Myocardial Infarction

Drugs mentioned

• Jardiance (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Myocardial Infarction | Phase 3 | Status: COMPLETED | Results posted: 2025-01-07